Schonfeld Strategic Advisors LLC Decreases Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

Schonfeld Strategic Advisors LLC lessened its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 40.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 116,915 shares of the company's stock after selling 79,435 shares during the period. Schonfeld Strategic Advisors LLC owned 0.18% of Vera Therapeutics worth $4,944,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of VERA. Huntington National Bank acquired a new position in Vera Therapeutics in the 4th quarter valued at about $26,000. Summit Investment Advisors Inc. lifted its holdings in Vera Therapeutics by 16.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after purchasing an additional 639 shares during the last quarter. AlphaQuest LLC acquired a new stake in Vera Therapeutics during the 4th quarter worth approximately $34,000. Alliancebernstein L.P. lifted its holdings in shares of Vera Therapeutics by 2.0% during the fourth quarter. Alliancebernstein L.P. now owns 40,350 shares of the company's stock worth $1,706,000 after buying an additional 800 shares in the last quarter. Finally, E Fund Management Co. Ltd. raised its stake in Vera Therapeutics by 22.3% in the 4th quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company's stock worth $262,000 after purchasing an additional 1,130 shares in the last quarter. 99.21% of the stock is owned by institutional investors.

Vera Therapeutics Stock Down 2.7 %

Shares of VERA traded down $0.61 during mid-day trading on Thursday, reaching $22.01. The company had a trading volume of 548,295 shares, compared to its average volume of 770,709. The firm has a 50-day moving average price of $24.48 and a 200 day moving average price of $34.98. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of -8.49 and a beta of 1.28. Vera Therapeutics, Inc. has a 52 week low of $18.53 and a 52 week high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period in the previous year, the company posted ($0.56) EPS. On average, sell-side analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. The Goldman Sachs Group began coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They set a "buy" rating and a $58.00 price objective on the stock. Guggenheim increased their price objective on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Cantor Fitzgerald lowered their price target on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a research report on Wednesday. HC Wainwright began coverage on shares of Vera Therapeutics in a research note on Monday. They issued a "buy" rating and a $75.00 price objective for the company. Finally, Wedbush cut their target price on Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $63.80.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.